On July 13, 2026, a Phase 4 clinical trial involving elamipretide was listed as recruiting on ClinicalTrials.gov. The trial, titled "Clinical Trial in Patients With Barth Syndrome- 4TAZPower," carries the identifier NCT07531251.
The study is registered as a Phase 4 trial, indicating it is being conducted after prior approval or authorization stages. Its current status is recruiting, meaning the trial is actively enrolling participants with Barth Syndrome.
No results or outcome data have been reported for this trial as of the listed date. The registration confirms only the trial's title, phase, and recruiting status.
Further details about the trial's design, endpoints, and enrollment criteria can be found on the official ClinicalTrials.gov listing. This brief reflects only the information available at the time of this update.
Readers interested in learning more about elamipretide can consult the compound overview for additional context.